CDKN2A and acute lymphoblastic leukemia: The results revealed no statistically significant differences (relapse: P = 0.071, mortality: P = 0.050), suggesting that CDKN2A/B deletion could not be considered to be related to relapse or mortality in pediatric ALL patients.